Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, net loss was USD 47.52 million compared to USD 41.04 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.72 USD | -8.70% | -9.06% | -9.92% |
Mar. 22 | Lyra Therapeutics Files $300 Million Mixed Shelf Offering | MT |
Mar. 21 | Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-9.92% | 282M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |